AnaptysBio Inc. is set to report second-quarter earnings after the bell on Tuesday, with revenue projected to decline 21% sequentially to $20.2 million, reflecting a 9% year-over-year drop. The loss per share is expected to widen to 13 cents, up from 96 cents in the prior quarter, according to analyst estimates.
The company’s shares have surged 234% from a 52-week low of $17.11 to $57.29, valuing the biotech at $1.67 billion. All 11 analysts covering the stock maintain Strong Buy ratings, with a mean price target of $86.64, implying 54% upside potential. TD Cowen’s Joseph Thome retained a Buy rating but trimmed his target to $70 from $75 on August 25.
Jemperli, a key revenue driver, contributed $24.7 million in royalties during the first quarter, a 44% increase. GSK recently announced the FDA accepted Jemperli’s priority review application for rectal cancer, with a regulatory decision expected by February 2027. Analysts at TD Cowen estimate peak U.S. sales for this indication could reach $290 million.
AnaptysBio’s other lead asset, imsidolimab, faces a December decision for generalized pustular psoriasis under a licensing agreement with Vanda Pharmaceuticals. The company completed a drug-development operations spin-off in April and subsequently announced a $100 million stock repurchase plan.
Forward earnings estimates have weakened over the past two months, with EPS projections falling 53% and revenue estimates down 14%, though they have since stabilized. The biotech’s forward price-to-earnings ratio remains negative at -59.6, underscoring ongoing investment in pipeline development despite near-term revenue pressures.
